{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:46:22Z","timestamp":1793778382385,"version":"4.6.1"},"reference-count":26,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,10,19]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, approved treatments have limited effects on hepatitis B surface antigen (HBsAg) and HBeAg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The phase 2 REEF-IT study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04439539\">NCT04439539<\/jats:ext-link>\n                      ) assessed safety, efficacy and pharmacokinetics of pegylated interferon-\u03b12a (PegIFN-\u03b12a) add-on to JNJ-73763989 (JNJ-3989)\u00b1bersacapavir+nucleos(t)ide analogues (NA) in not currently treated, HBeAg+chronic hepatitis B.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Participants received JNJ-3989 (200\u2009mg every 4 weeks)+NA\u00b1bersacapavir (250\u2009mg daily) for 36\u201352 weeks (induction) followed by 12 weeks of PegIFN-\u03b12a (180\u2009\u00b5g weekly) add-on. The primary endpoint was the proportion of participants with HBsAg seroclearance 24 weeks after stopping all treatment including NA. Changes in viral markers, safety and pharmacokinetics were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      49\/54 (91%) enrolled participants completed the study; 52% were male, with mean age of 33.6 years. No participant achieved the primary endpoint; one met NA completion criteria. 11\/54 (20.4%) participants achieved HBsAg seroclearance at least once, 6 of them maintained it until Follow-up Week 48 (FUW48). Overall mean (SE) change from baseline in HBsAg of \u20132.85 (0.13), \u20133.61 (0.18) and \u20132.63 (0.26)log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL were observed at end of induction, end of treatment and FUW48. 16\/53 (30.2%) participants reached HBeAg seroclearance at least once; 12 maintained it until FUW48. Similar proportions of participants experienced an adverse event (AE) during induction (83.3%), PegIFN-\u03b12a add-on (85.7%) and follow-up (64.7%). There were no deaths or serious AEs; two participants discontinued PegIFN-\u03b12a.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this population, adding PegIFN-\u03b12a increased HBsAg declines after reductions by JNJ-3989; 20.4% achieved HBsAg seroclearance at least once. Treatment was generally safe with acceptable tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04439539\">NCT04439539<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-336592","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:55:17Z","timestamp":1762325717000},"page":"1043-1054","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study"],"prefix":"10.1136","volume":"75","clinical-trial-number":[{"clinical-trial-number":"nct04439539","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04439539","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03982186","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04129554","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04439539","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04667104","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06537414","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-0094","authenticated-orcid":false,"given":"Patrick T F","family":"Kennedy","sequence":"first","affiliation":[{"name":"Centre for Immunobiology and Infection, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London Faculty of Medicine and Dentistry, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Hepatology, Hospital General Universitari Valle, Pg. de la Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdal","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Trabzon Karadeniz Technical University Farabi Hospital, Trabzon, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Hepatology, Universit\u00e9 de Paris-Cit\u00e9, INSERM UMR1149, Department of Hepatology, AP-HP H\u00f4pital Beaujon, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-8931","authenticated-orcid":false,"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Klyashtornyy","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-2572","authenticated-orcid":false,"given":"Thomas Naoki","family":"Kakuda","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Guinard-Azadian","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-8206","authenticated-orcid":false,"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026060303401274000_75.5.1043.1","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026060303401274000_75.5.1043.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28280"},{"key":"2026060303401274000_75.5.1043.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29323"},{"key":"2026060303401274000_75.5.1043.4","doi-asserted-by":"crossref","first-page":"101360","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"2026060303401274000_75.5.1043.5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026060303401274000_75.5.1043.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.010"},{"key":"2026060303401274000_75.5.1043.7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060303401274000_75.5.1043.8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","article-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026060303401274000_75.5.1043.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.046"},{"key":"2026060303401274000_75.5.1043.10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"2026060303401274000_75.5.1043.11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep4.1875","article-title":"Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B","volume":"6","author":"Choi","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026060303401274000_75.5.1043.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.019"},{"key":"2026060303401274000_75.5.1043.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324646"},{"key":"2026060303401274000_75.5.1043.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01097-3"},{"key":"2026060303401274000_75.5.1043.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101487","article-title":"Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment","volume":"7","author":"Hui","year":"2025","journal-title":"JHEP Rep"},{"key":"2026060303401274000_75.5.1043.16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.012"},{"key":"2026060303401274000_75.5.1043.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333026"},{"key":"2026060303401274000_75.5.1043.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101516","article-title":"Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study","volume":"7","author":"Gane","year":"2025","journal-title":"JHEP Rep"},{"key":"2026060303401274000_75.5.1043.19","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"2026060303401274000_75.5.1043.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"2026060303401274000_75.5.1043.21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026060303401274000_75.5.1043.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405485"},{"key":"2026060303401274000_75.5.1043.23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"2026060303401274000_75.5.1043.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.044"},{"key":"2026060303401274000_75.5.1043.25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2022.12.017","article-title":"A critique and systematic review of the clinical utility of hepatitis B core-related antigen","volume":"78","author":"Adraneda","year":"2023","journal-title":"J Hepatol"},{"key":"2026060303401274000_75.5.1043.26","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2025.2475847","article-title":"Mechanisms underlying delayed loss of HBeAg and HBV DNA following HBsAg seroclearance in PEG-IFN\u03b1 treated patients of chronic hepatitis B","volume":"14","author":"Jiang","year":"2025","journal-title":"Emerg Microbes Infect"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-336592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:40:46Z","timestamp":1780483246000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-336592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/gutjnl-2025-336592"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-336592","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}